CAR-T cell therapy for autoimmune diseases that resist treatment
Part of Bones, joints & muscles, Brain & nervous system, Cancer, Eyes & vision, Immune system & allergy, Skin clinical trials.
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lupus, scleroderma, inflammatory myositis, rheumatoid arthritis, neuromyelitis optica, multiple sclerosis, myasthenia gravis, or antiphospholipid syndrome.
- You have tried at least two standard treatments for your condition but they did not work or caused serious side effects.
- You are between 18 and 80 years old (if 75–80, a special health check is needed).
- Your heart, lungs, and liver are working well enough, with no unstable heart disease or severe lung problems.
- You have not had rituximab in the last 4 months, and you do not have active infections like hepatitis B, C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune rheumatic diseases like rheumatoid arthritis, lupus, or scleroderma that have not responded well to standard treatments. The therapy works by modifying your own immune cells to help control the disease.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
This trial tests if a special immune cell therapy (CAR-T) can help people with certain autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that haven't improved with standard treatments. It is a very early phase study to check safety and effectiveness.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.